JP2019524888A - 血液がんの治療のためのＰＰＡＲγアゴニスト - Google Patents

血液がんの治療のためのＰＰＡＲγアゴニスト Download PDF

Info

Publication number
JP2019524888A
JP2019524888A JP2019530367A JP2019530367A JP2019524888A JP 2019524888 A JP2019524888 A JP 2019524888A JP 2019530367 A JP2019530367 A JP 2019530367A JP 2019530367 A JP2019530367 A JP 2019530367A JP 2019524888 A JP2019524888 A JP 2019524888A
Authority
JP
Japan
Prior art keywords
leukemia
subject
effective amount
therapeutically effective
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524888A5 (OSRAM
Inventor
クリストス マントゾロス
クリストス マントゾロス
Original Assignee
インテクリン セラピューティクス インコーポレイテッド
インテクリン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インテクリン セラピューティクス インコーポレイテッド, インテクリン セラピューティクス インコーポレイテッド filed Critical インテクリン セラピューティクス インコーポレイテッド
Publication of JP2019524888A publication Critical patent/JP2019524888A/ja
Publication of JP2019524888A5 publication Critical patent/JP2019524888A5/ja
Priority to JP2022091309A priority Critical patent/JP2022116304A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2019530367A 2016-08-18 2017-08-18 血液がんの治療のためのＰＰＡＲγアゴニスト Pending JP2019524888A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022091309A JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのＰＰＡＲγアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376749P 2016-08-18 2016-08-18
US62/376,749 2016-08-18
PCT/US2017/047578 WO2018035446A1 (en) 2016-08-18 2017-08-18 PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022091309A Division JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのＰＰＡＲγアゴニスト

Publications (2)

Publication Number Publication Date
JP2019524888A true JP2019524888A (ja) 2019-09-05
JP2019524888A5 JP2019524888A5 (OSRAM) 2020-10-01

Family

ID=61197183

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530367A Pending JP2019524888A (ja) 2016-08-18 2017-08-18 血液がんの治療のためのＰＰＡＲγアゴニスト
JP2022091309A Withdrawn JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのＰＰＡＲγアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022091309A Withdrawn JP2022116304A (ja) 2016-08-18 2022-06-06 血液がんの治療のためのＰＰＡＲγアゴニスト

Country Status (12)

Country Link
US (1) US20210379049A1 (OSRAM)
EP (1) EP3500268A4 (OSRAM)
JP (2) JP2019524888A (OSRAM)
KR (1) KR20190064573A (OSRAM)
CN (1) CN110461329A (OSRAM)
AU (1) AU2017313839A1 (OSRAM)
BR (1) BR112019003130A2 (OSRAM)
CA (1) CA3034258A1 (OSRAM)
EA (1) EA201990512A1 (OSRAM)
MX (1) MX2019001979A (OSRAM)
SG (2) SG10202101501PA (OSRAM)
WO (1) WO2018035446A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
JP2020515639A (ja) 2017-04-03 2020-05-28 コヒラス・バイオサイエンシズ・インコーポレイテッド 進行性核上性麻痺の処置のためのＰＰＡＲγアゴニスト
WO2020243058A1 (en) * 2019-05-30 2020-12-03 Coherus Biosciences, Inc. Compositions and methods to treat cancer
JP2022104746A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗がん剤
JP2022104747A (ja) * 2020-12-29 2022-07-11 国立研究開発法人国立がん研究センター 抗ウイルス剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256208A (ja) * 1999-03-09 2000-09-19 Univ Osaka 抗炎症剤、単球系細胞の増殖抑制剤
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2950798B1 (en) * 2013-01-30 2021-05-12 Intekrin Therapeutics, Inc. Ppar-gamma agonist for treatment of multiple sclerosis
WO2017211830A1 (en) * 2016-06-08 2017-12-14 Support-Venture Gmbh Pharmaceutical combinations for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000256208A (ja) * 1999-03-09 2000-09-19 Univ Osaka 抗炎症剤、単球系細胞の増殖抑制剤
JP2007507537A (ja) * 2003-10-03 2007-03-29 アムジェン インコーポレーテッド 強力な抗糖尿病薬化合物の塩および多形体
JP2010265216A (ja) * 2009-05-14 2010-11-25 Takeda Chem Ind Ltd 複素環化合物

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN HEMATOLOGY, vol. 2009, JPN6021020544, 2009, pages 6 pages, ISSN: 0004699789 *
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, JPN6021020555, 2013, pages 979 - 992, ISSN: 0004518948 *
BLOOD, vol. 113(16), JPN6021020549, 2009, pages 3655 - 3665, ISSN: 0004518944 *
BLOOD, vol. 118(22), JPN6021020543, 2011, pages 5872 - 5882, ISSN: 0004699788 *
CANCER CAUSES CONTROL, vol. 20, JPN6021020554, 2009, pages 193 - 199, ISSN: 0004518947 *
CLINICAL IMMUNOLOGY, vol. 113, JPN6021020551, 2004, pages 203 - 213, ISSN: 0004518945 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 58, JPN6021020546, 2006, pages 1 - 14, ISSN: 0004518942 *
DIABETES CARE, vol. 37, JPN6021020540, 2014, pages 1918 - 1923, ISSN: 0004699786 *
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 755, JPN6021020557, 2015, pages 50 - 57, ISSN: 0004518949 *
HTTPS://PROFESSIONAL.DIABETES.ORG/ABSTRACT/T0903131-SELECTIVE-MODULATOR-PPAR-GAMMA-ACTIVITY-INCREASE, JPN6021020541, 2004, ISSN: 0004699787 *
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 83(3), JPN6021020552, 2006, pages 254 - 258, ISSN: 0004518946 *
LIFE SCIENCES, vol. 135, JPN6021020547, 2015, pages 55 - 67, ISSN: 0004518943 *
PPAR RESEARCH, vol. 2008, JPN6021020537, 2008, pages 9 pages, ISSN: 0004699785 *

Also Published As

Publication number Publication date
CA3034258A1 (en) 2018-02-22
SG11201901320WA (en) 2019-03-28
WO2018035446A1 (en) 2018-02-22
KR20190064573A (ko) 2019-06-10
MX2019001979A (es) 2019-09-19
AU2017313839A1 (en) 2019-03-07
BR112019003130A2 (pt) 2019-05-21
EP3500268A1 (en) 2019-06-26
CN110461329A (zh) 2019-11-15
SG10202101501PA (en) 2021-03-30
EP3500268A4 (en) 2020-04-15
US20210379049A1 (en) 2021-12-09
EA201990512A1 (ru) 2019-08-30
JP2022116304A (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
JP2022116304A (ja) 血液がんの治療のためのＰＰＡＲγアゴニスト
EP3265087B1 (en) Method of treatment with tradipitant
CN102908347A (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
JP6862404B2 (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
CA3100792A1 (en) Methods and compositions for treatment of alzheimer's disease
EP3866804A1 (en) Combinations for immune-modulation in cancer treatment
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
JPH08169821A (ja) 血管漏出症候群を処置するための方法
JP2018526440A (ja) 免疫系を刺激するためのインドール化合物の使用
JP2019524888A5 (OSRAM)
JP2024523126A (ja) Ｎｒｈ、ｎａｒｈ、及びそれらの還元誘導体を用いた免疫関連障害、腎障害、肝障害、溶血性障害、及び酸化的ストレス関連障害の処置
EP3380104A1 (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
CN117959303A (zh) 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
KR20220124739A (ko) 암의 치료를 위한 병용 요법
WO2020167969A1 (en) Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease
MD4844C1 (ro) Utilizare a derivatului de glutarimidă pentru depăşirea rezistenţei la steroizi
CN120659608A (zh) 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合
WO2022161364A1 (zh) 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法
RU2822394C1 (ru) Способы лечения
CN117018202A (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
KR20230042065A (ko) 테모졸로마이드와 돌연변이 idh1 효소 억제제의 조합 의약
HK1248552B (en) Method of treatment with tradipitant

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200930

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210319

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210531

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220207